Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...
Legend Biotech (LEGN) Gets a Buy from Truist Financial
In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).
Friday's big stock stories: What’s likely to move the market in the next trading session
Stocks slid on Thursday as Fed Chair Jerome Powell signaled that policymakers don't need to be in a hurry to cut rates.
This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...
GlobalData on MSN20h
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
MarketWatch17h
Immutep ADRs Climb on Positive Efti Trial Results
Shares had fallen 22% year-to-date when the market closed Wednesday. The biotechnology company said before the bell that mature survival data for patients treated with the combination were well above ...
Strategic Acquisition and Oncology Focus Justify BioNTech’s Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...